336 related articles for article (PubMed ID: 28004148)
1. An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice.
Hasib A; Ng MT; Gault VA; Khan D; Parthsarathy V; Flatt PR; Irwin N
Diabetologia; 2017 Mar; 60(3):541-552. PubMed ID: 28004148
[TBL] [Abstract][Full Text] [Related]
2. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
[TBL] [Abstract][Full Text] [Related]
3. Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Eur J Pharmacol; 2018 Sep; 834():126-135. PubMed ID: 30025814
[TBL] [Abstract][Full Text] [Related]
4. Biological Activity and Antidiabetic Potential of C-Terminal Octapeptide Fragments of the Gut-Derived Hormone Xenin.
Martin CM; Parthsarathy V; Hasib A; Ng MT; McClean S; Flatt PR; Gault VA; Irwin N
PLoS One; 2016; 11(3):e0152818. PubMed ID: 27032106
[TBL] [Abstract][Full Text] [Related]
5. A GIP/xenin hybrid in combination with exendin-4 improves metabolic status in db/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed mice.
Craig SL; Perry RA; Vyavahare SS; Ng MT; Gault VA; Flatt PR; Irwin N
Biochem Pharmacol; 2020 Jan; 171():113723. PubMed ID: 31756326
[TBL] [Abstract][Full Text] [Related]
6. A novel neurotensin/xenin fusion peptide enhances β-cell function and exhibits antidiabetic efficacy in high-fat fed mice.
Perry RA; Craig SL; Gault VA; Flatt PR; Irwin N
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34370015
[TBL] [Abstract][Full Text] [Related]
7. A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing properties.
Parthsarathy V; Irwin N; Hasib A; Martin CM; McClean S; Bhat VK; Ng MT; Flatt PR; Gault VA
Biochim Biophys Acta; 2016 Apr; 1860(4):757-64. PubMed ID: 26802310
[TBL] [Abstract][Full Text] [Related]
8. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
Irwin N; Hunter K; Montgomery IA; Flatt PR
Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
[TBL] [Abstract][Full Text] [Related]
9. Exendin-4(Lys
Hasib A; Ng MT; Tanday N; Craig SL; Gault VA; Flatt PR; Irwin N
Diabetes Metab Res Rev; 2019 Mar; 35(3):e3106. PubMed ID: 30499633
[TBL] [Abstract][Full Text] [Related]
10. Antidiabetic effects and sustained metabolic benefits of sub-chronic co-administration of exendin-4/gastrin and xenin-8-Gln in high fat fed mice.
Hasib A; Khan D; Craig SL; Gault VA; Flatt PR; Irwin N
Eur J Pharmacol; 2019 Dec; 865():172733. PubMed ID: 31614140
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety.
Taylor AI; Irwin N; McKillop AM; Patterson S; Flatt PR; Gault VA
J Endocrinol; 2010 Oct; 207(1):87-93. PubMed ID: 20631047
[TBL] [Abstract][Full Text] [Related]
12. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice.
Millar PJ; Pathak V; Moffett RC; Pathak NM; Bjourson AJ; O'Kane MJ; Flatt PR; Gault VA
Mol Cell Endocrinol; 2016 Jan; 420():37-45. PubMed ID: 26607806
[TBL] [Abstract][Full Text] [Related]
13. Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25.
Martin CM; Gault VA; McClean S; Flatt PR; Irwin N
Biochem Pharmacol; 2012 Aug; 84(3):312-9. PubMed ID: 22561048
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of the biological activity of xenin-25 degradation fragment peptides.
Martin CM; Parthsarathy V; Pathak V; Gault VA; Flatt PR; Irwin N
J Endocrinol; 2014 May; 221(2):193-200. PubMed ID: 24520141
[TBL] [Abstract][Full Text] [Related]
15. Comparison of independent and combined effects of the neurotensin receptor agonist, JMV-449, and incretin mimetics on pancreatic islet function, glucose homeostasis and appetite control.
Craig SL; Gault VA; Shiels CE; Hamscher G; Irwin N
Biochim Biophys Acta Gen Subj; 2021 Aug; 1865(8):129917. PubMed ID: 33964357
[TBL] [Abstract][Full Text] [Related]
16. Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential.
Pathak NM; Pathak V; Gault VA; McClean S; Irwin N; Flatt PR
Biochem Pharmacol; 2018 Sep; 155():264-274. PubMed ID: 30028989
[TBL] [Abstract][Full Text] [Related]
17. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
McShane LM; Irwin N; O'Flynn D; Franklin ZJ; Hewage CM; O'Harte FP
J Endocrinol; 2016 Jun; 229(3):319-30. PubMed ID: 27098830
[TBL] [Abstract][Full Text] [Related]
18. A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice.
Irwin N; Pathak V; Flatt PR
Diabetes; 2015 Aug; 64(8):2996-3009. PubMed ID: 25883113
[TBL] [Abstract][Full Text] [Related]
19. Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism.
Wice BM; Wang S; Crimmins DL; Diggs-Andrews KA; Althage MC; Ford EL; Tran H; Ohlendorf M; Griest TA; Wang Q; Fisher SJ; Ladenson JH; Polonsky KS
J Biol Chem; 2010 Jun; 285(26):19842-53. PubMed ID: 20421298
[TBL] [Abstract][Full Text] [Related]
20. Xenin-25[Lys13PAL]: a novel long-acting acylated analogue of xenin-25 with promising antidiabetic potential.
Gault VA; Martin CM; Flatt PR; Parthsarathy V; Irwin N
Acta Diabetol; 2015 Jun; 52(3):461-71. PubMed ID: 25374384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
